AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 86 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2021. The put-call ratio across all filers is 0.52 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $207,339 | -38.4% | 20,130 | -1.4% | 0.00% | – |
| Q2 2023 | $336,324 | +137.6% | 20,408 | +32.1% | 0.00% | – |
| Q1 2023 | $141,522 | -30.5% | 15,450 | -45.7% | 0.00% | – |
| Q4 2022 | $203,702 | +42.4% | 28,450 | 0.0% | 0.00% | – |
| Q3 2022 | $143,000 | +90.7% | 28,450 | -7.8% | 0.00% | – |
| Q2 2022 | $75,000 | -50.0% | 30,850 | +40.5% | 0.00% | – |
| Q1 2022 | $150,000 | -5.1% | 21,950 | +12.3% | 0.00% | – |
| Q4 2021 | $158,000 | -15.1% | 19,550 | +3.2% | 0.00% | – |
| Q3 2021 | $186,000 | +44.2% | 18,950 | -1.0% | 0.00% | – |
| Q2 2021 | $129,000 | -11.6% | 19,150 | +18.6% | 0.00% | – |
| Q1 2021 | $146,000 | +114.7% | 16,150 | +57.6% | 0.00% | – |
| Q4 2020 | $68,000 | +21.4% | 10,250 | -7.2% | 0.00% | – |
| Q3 2020 | $56,000 | -47.7% | 11,050 | -16.2% | 0.00% | – |
| Q2 2020 | $107,000 | – | 13,183 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |